They couldn't dose the highest dosage since healthy volunteers experience adverse effects since their dopamine receptors are not down regulated as they are in Parkinson's patients. This is a normal occurrence for the drug.
The study was stopped early because of side effects among the healthy p1 volunteers...they were getting quite ill from the dose that is needed to stop an off-motor event. Not life threatening, just quite ill temporarily. It is likely that this will not happen to Parkinson's patients. Nevertheless, the next step is not clear at this point. Could result in a fast track toward approval or a slower track.
Market Data 
Markets 
AI
